Axitinib

Generic Name: Axitinib

Brand Names: Inlyta, Axitinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₈N_₄OS

CAS Number: 319460-85-0

Unique Ingredient Identifier: C9LVQ0YUXG

Background: Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...

Indication: Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Thyroid cancer

Associated Therapies: First Line Chemotherapy

Clinical Trials

Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

Phase 2

Completed

Conditions: Soft Tissue Sarcomas
Alveolar Soft Part Sarcoma

Interventions: Drug: Axitinib
Drug: Pembrolizumab

First Posted Date: 2015-12-22

Last Posted Date: 2024-07-12

Lead Sponsor: Jonathan Trent, MD, PhD

Target Recruit Count: 33

Registration Number: NCT02636725

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)

Phase 2

Completed

Conditions: cT2a N0NxM0 Renal Tumor

Interventions: Drug: AXITINIB

First Posted Date: 2015-11-05

Last Posted Date: 2017-07-25

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 21

Registration Number: NCT02597322

Locations: 🇫🇷
Bicêtre Hospital, Le Kremlin Bicêtre, France

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

Phase 2

Completed

Conditions: Metastatic Renal Cell Cancer

Interventions: Drug: Axitinib

First Posted Date: 2015-10-20

Last Posted Date: 2023-06-29

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT02579811

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 1 locations

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Phase 2

Terminated

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sunitinib
Drug: Temsirolimus
Drug: Sorafenib
Drug: Pazopanib
Drug: Everolimus
Drug: Axitinib

First Posted Date: 2015-09-25

Last Posted Date: 2018-10-12

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 4

Registration Number: NCT02560012

Locations: 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States

SLM + Axitinib for Clear Cell RCC

Phase 1

Active, not recruiting

Conditions: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)

Interventions: Drug: Selenomethionine (SLM)
Drug: Axitinib

First Posted Date: 2015-08-28

Last Posted Date: 2024-08-09

Lead Sponsor: Bilal G. Rahim

Target Recruit Count: 46

Registration Number: NCT02535533

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma

Phase 2

Completed

Conditions: Papillary Renal Cell Carcinoma

Interventions: Drug: Axitinib

First Posted Date: 2015-07-03

Last Posted Date: 2022-09-06

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 44

Registration Number: NCT02489695

Locations: 🇫🇷
ICO Paul Papin, Angers, France
🇫🇷
Chu Bordeaux, Bordeaux, France
🇫🇷
Centre Francois Baclesse, Caen, France

and more 7 locations

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Conditions: Solid Tumors

First Posted Date: 2015-02-03

Last Posted Date: 2021-02-15

Lead Sponsor: Tracon Pharmaceuticals Inc.

Registration Number: NCT02354612

Locations: 🇺🇸
UCLA, Santa Monica, California, United States

Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor

Phase 2

Completed

Conditions: Solitary Fibrous Tumor

Interventions: Drug: Axitinib

First Posted Date: 2014-10-10

Last Posted Date: 2021-09-28

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 17

Registration Number: NCT02261207

Locations: 🇮🇹
Fondazione IRCCS Istituto Naazionale dei Tumori, Milan, MI, Italy

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

Phase 1

Completed

Conditions: Refractory or Recurrent Solid Tumors, Excluding CNS Tumors

Interventions: Drug: Axitinib

First Posted Date: 2014-06-17

Last Posted Date: 2018-01-29

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 51

Registration Number: NCT02164838

Locations: 🇺🇸
Childrens Hospital of Orange County, Orange, California, United States
🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

and more 18 locations

Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

Completed

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: Axitinib

First Posted Date: 2014-06-05

Last Posted Date: 2024-03-08

Lead Sponsor: Pfizer

Target Recruit Count: 111

Registration Number: NCT02156895

Locations: 🇰🇷
Pfizer Tower, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy